Tuesday, 19 Jun 2018

You are here

Sorting Out the Complexities of Autoimmunity with Immune Checkpoint Inhibitor Therapy

The current issue of Annals of Internal Medicine features an editorial by Dr. Len Calabrese that focuses on a systematic review published in the journal on autoimmune and inflammatory complications due to checkpoint inhibitor (CPI) therapy for cancer. He points out that "immunologic checkpoints are brakes on an activated immune system; and that CPIs remove or diminish these brakes and reinvigorate an exhausted immune response". (Citation source: https://buff.ly/2CQia03)

With growing use of 6 marketed CPI, we have seen numerous autoimmune and/or autoinflammatory complications associated with CPIs; collectively these have been called as immune-related adverse events (irAEs).  Hundreds of these cases have been described and range from RA, PsA, PsO, PMR, etc.  Such immune mediated inflammatory disorders (IMIDs) have been excluded from clinical trials with CPIs. 

Given that many IMIDs are at increased risk for neoplasia, it is unknown what will happen when an IMID meets a CPI?

Suarez-Almozar and colleagues reported their findings of a systematic review of CPIs given to patients with autoimmune and the spectrum of irAEs .

Their review was narrowed to 49 publications and included 123 patients from in  30 different autoimmune and/or autoinflammatory diseases. These patients were treated with either ipilimumab (a cytotoxic T lymphocyte–associated protein 4 inhibitor) or one of several anti–PD-1/PD-L1 agents in isolation.

Nearly three quarters a de novo irAE or had a flare of their underlying autoimmune disease.   Dr. Calabrese points out that there were more de novo irAEs with ipilimumab and more flares of preexisting disease with therapies targeting PD-1.

Most flares and irAEs were managed with corticosteroids and a minority (16%) required other immunosuppressive therapies. Adverse events improved in more than half of patients without discontinuation of CPI therapy. Three patients died of adverse events.

Flares and irAEs in patients with autoimmune disease who are receiving CPIs can often be managed without discontinuing therapy, although some events may be severe and fatal. 

Both authors call for prospective studies of CPIs in patients with preexisting autoimmunity. Systematic reviews  may be marred by reporting bias and channeling bias.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.

MMWR: Cannabis Use in the Colorado Workers

MMWR reports that eight states, including Colorado, have legalized recreational marijuana for use by adults and that a study of use in Colorado has shown that nearly 15% of Colorado adult workers have used marijuana in the past 30 days. Use was highest among young adults, especially men, working in the Accommodation/Food Services and Food Preparation/Serving industries.